BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ponatinib: Additional Phase II data

Updated interim data from 392 evaluable patients in the single-arm, international, pivotal Phase II PACE trial showed that once-daily 45 mg oral ponatinib produced a MCyR rate of 47% in patients with chronic phase CML (n=248), with 39% of patients achieving a complete cytogenetic response (CCyR), at a median follow-up of 5.6 months. In 57 evaluable chronic phase CML patients with the T315I variant of BCR-ABL tyrosine kinase, ponatinib led to MCyR and CCyR rates...

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >